[Effects of the enterosorbent SUMS-1 on isoniazid pharmacokinetics and lipid peroxidation in patients with pulmonary tuberculosis and drug-induced hepatic lesions].
The use of the enterosorbent SUMS-1 in the combined therapy for pulmonary tuberculosis patients with drug-induced toxic hepatic lesion arrests the clinical and laboratory manifestations of endotoxicosis, removes antibiotic intolerance, increases the elimination rate of isoniazid, and reduces its distribution scope, the area beneath the kinetic curve being unchanged. The plasma concentrations of primary products and after-products of lipid peroxidation products during enterosorbent therapy decline and the levels of ceruloplasmin and alpha-tocopherol remain unchanged.
Adult↗